Effect of D, alpha-tocopheryl succinate and polyethylene glycol on performance tests after fluid percussion brain injury.
One hundred and one rats were administered either D, alpha-tocopheryl succinate plus polyethylene glycol (PEG), PEG, or saline 30 min prior to or 5 min after moderate fluid percussion brain injury. Mortality rates, performance on beam balance and beam-walking tasks, and body weight were assessed daily for 10 days. With preinjury administration, mortality rate was reduced from 31% with saline to 9% with PEG and 9% with D, alpha-tocopheryl succinate plus PEG. With postinjury administration, mortality rate was reduced from 36% with saline to 20% with PEG and to 10% with the D, alpha-tocopheryl succinate plus PEG combination. With administration prior to injury, PEG and D, alpha-tocopheryl succinate plus PEG reduced the deficits seen on beam balance testing on days 1-3 after injury. On beam walking, PEG and D, alpha-tocopheryl succinate plus PEG reduced deficits compared to those in saline-injected animals on days 1 and 2 and on day 1 after injury, respectively. A strongly protective effect of PEG and of D, alpha-tocopheryl succinate plus PEG was seen with preinjury administration. With postinjury administration, D, alpha-tocopheryl succinate plus PEG reduced deficits on beam balance testing compared to animals receiving both saline and PEG on days 1-3 after injury. On beam-walking latencies, D, alpha-tocopheryl succinate plus PEG reduced deficits on days 1 and 2 after injury compared to saline and to PEG. Both PEG and D, alpha-tocopheryl succinate plus PEG reduced weight loss after injury compared to saline. The protective effects of these agents and their relatively low toxicity and high lipid solubility give them potential for the treatment of human head injury.
Department of Surgery, Richard Roland Reynolds Neurosurgical Research Laboratories, Richmond, Virginia.
G L
GL
Clifton
B G
BG
Lyeth
L W
LW
Jenkins
W C
WC
Taft
R J
RJ
DeLorenzo
R L
RL
Hayes
D000818:Animals; D001930:Brain Injuries / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D004359:Drug Therapy, Combination; D008297:Male; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D051381:Rats; D011919:Rats, Inbred Strains; D024505:Tocopherols; D014810:Vitamin E / Q000031:analogs & derivatives* / Q000627:therapeutic use
D014810:Vitamin E; D011092:Polyethylene Glycols; D024505:Tocopherols